Biological therapies for eosinophilic gastrointestinal diseases

Joshua Brian Wechsler*, Ikuo Hirano

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


The scientific basis and the clinical application of mAb therapies that target specific immunologic pathways for eosinophilic gastrointestinal diseases are areas of active interest. There is a growing recognition of a subset of patients with eosinophilic esophagitis whose disease does not respond well to topical steroids or elimination diets. In addition, long-term use of corticosteroids presents possible risks that are currently being evaluated. Systemic therapy with a biologic agent offers potential advantages as a global approach that could limit the need for multiple, locally active medical therapies and allergen avoidance. The identification of novel biologic strategies is ongoing, and the recent validation of instruments and outcome measures to assess disease activity has proved essential in demonstrating efficacy. Studies using biologics that target IL-13 pathways in the treatment of eosinophilic esophagitis have demonstrated substantial promise.

Original languageEnglish (US)
Pages (from-to)24-31.e2
JournalJournal of Allergy and Clinical Immunology
Issue number1
StatePublished - Jul 2018


  • Eosinophilic esophagitis
  • dysphagia
  • esophageal strictures
  • esophagitis
  • food allergy
  • gastroesophageal reflux disease

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Biological therapies for eosinophilic gastrointestinal diseases'. Together they form a unique fingerprint.

Cite this